Recurrences following primary osteosarcoma in adolescents and adults previously treated with chemotherapy
| Autor: | J.P. Dales, F. Volot, C. Mercier, Florence Duffaud, Pascal Thomas, R. Favre, M. Baciuchka-Palmaro, L. Digue |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Adolescent medicine.medical_treatment Population Bone Neoplasms Antineoplastic Combined Chemotherapy Protocols medicine Humans Age of Onset Neoplasm Metastasis Child education Survival analysis Retrospective Studies Osteosarcoma education.field_of_study Chemotherapy business.industry Retrospective cohort study Middle Aged medicine.disease Survival Analysis Confidence interval Surgery Treatment Outcome Oncology Female Neoplasm Recurrence Local Age of onset Metastasectomy business Follow-Up Studies |
| Zdroj: | European Journal of Cancer. 39:2050-2057 |
| ISSN: | 0959-8049 |
| DOI: | 10.1016/s0959-8049(03)00435-0 |
| Popis: | In this retrospective analysis, we report on the detailed management of 33 recurrent osteosarcoma patients from a population of 81 adolescents and adults previously treated (between November 1979 and November 1998) at the La Timone Adults Hospital, for an extremity-localised osteosarcoma. The site of the first recurrence was limited to the lung in 24 patients (73%), was local in 4 patients (12%), at multiple sites in 4 patients (12%), and limited to the bone for 1 patient (3%). The median interval between the diagnosis of the primary osteosarcoma and the first recurrence was 16 months (range 4–108 months). For all patients, the treatment combined aggressive chemotherapy and surgical resection of the recurrences whenever possible. 19 patients (58%) achieved a second complete remission. The median follow-up time from the first recurrence was 18 months (range 4–150 months). For all patients, the median overall survival from first recurrence was 17 months (95% confidence interval (CI), 11–22 months) and the projected 3and 5-year survival rates were 31.6 and 23.7%, respectively. Patients with a second complete remission had a better 5-year survival than patients without (44.6% versus 0%, P=0.001). The achievement of a second complete remission has an independent significant prognostic value for an improved survival. Aggressive surgery with the removal of recurrence sites combined with multiagent chemotherapy can either cure patients with recurrent osteosarcoma or significantly prolong their survival. # 2003 Elsevier Ltd. All rights reserved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect